shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson’s disease model

Alevtina D. Zharikov, …, J. Timothy Greenamyre, Edward A. Burton

*J Clin Invest.* 2015;125(7):2721-2735. [https://doi.org/10.1172/JCI64502](https://doi.org/10.1172/JCI64502).

Multiple convergent lines of evidence implicate both α-synuclein (encoded by *SCNA*) and mitochondrial dysfunction in the pathogenesis of sporadic Parkinson’s disease (PD). Occupational exposure to the mitochondrial complex I inhibitor rotenone increases PD risk; rotenone-exposed rats show systemic mitochondrial defects but develop specific neuropathology, including α-synuclein aggregation and degeneration of substantia nigra dopaminergic neurons. Here, we inhibited expression of endogenous α-synuclein in the adult rat substantia nigra by adeno-associated virus–mediated delivery of a short hairpin RNA (shRNA) targeting the endogenous rat *Snca* transcript. Knockdown of α-synuclein by ~35% did not affect motor function or cause degeneration of nigral dopaminergic neurons in control rats. However, in rotenone-exposed rats, progressive motor deficits were substantially attenuated contralateral to α-synuclein knockdown. Correspondingly, rotenone-induced degeneration of nigral dopaminergic neurons, their dendrites, and their striatal terminals was decreased ipsilateral to α-synuclein knockdown. These data show that α-synuclein knockdown is neuroprotective in the rotenone model of PD and indicate that endogenous α-synuclein contributes to the specific vulnerability of dopaminergic neurons to systemic mitochondrial inhibition. Our findings are consistent with a model in which genetic variants influencing α-synuclein expression modulate cellular susceptibility to environmental exposures in PD patients. shRNA targeting the *SNCA* transcript should be further evaluated as a possible neuroprotective therapy in PD.

Find the latest version:

http://jci.me/64502-pdf
shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson’s disease model

Alevtina D. Zharikov,1,2,3 Jason R. Cannon,1,2,3 Victor Tapias,1,2 Qing Bai,1,2 Max P. Horowitz,1,2 Vipul Shah,1,2 Amina El Ayadi,1,2 Teresa G. Hastings,1,2 J. Timothy Greenamyre,1,2,3 and Edward A. Burton1,2,3,4

1Pittsburgh Institute for Neurodegenerative Diseases and 2Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. 3Geriatric Research Education and Clinical Center, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA. 4Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Introduction

Parkinson’s disease (PD) is characterized pathologically by degeneration of discrete groups of neurons in the central, autonomic, and enteric nervous systems; the cardinal motor signs of PD (tremor, rigidity, and bradykinesia) are caused by loss of substantia nigra dopaminergic neurons, which are particularly vulnerable to pathogenesis (1). Some remaining neurons show intracellular inclusions — Lewy bodies and Lewy neurites — containing deposits of insoluble α-synuclein (2–4). Variants in the SNCA gene, encoding α-synuclein, modulate both PD risk (5–7) and α-synuclein expression levels (8), suggesting that α-synuclein may be involved in pathogenesis. This is supported by rare Mendelian PD phenocopies caused by SNCA gene duplications (9) and triplications (10) that increase α-synuclein expression levels (11) and by SNCA missense mutations that alter the amino acid sequence and biophysical properties of α-synuclein (12–14). However, common SNCA variants are insufficient to cause PD alone; other factors, including environmental exposures, contribute significantly to pathogenesis.

An important role for mitochondrial dysfunction in the pathogenesis of PD is suggested by the following observations: multiple tissues from PD patients show deficits in mitochondrial function, particularly complex I of the respiratory chain (15, 16); the substantia nigra in PD shows consumption of endogenous antioxidants and severe oxidative damage (17); loss-of-function mutations in several genes encoding proteins with mitochondrial functions cause early-onset parkinsonism (18–20); there is a strong epidemiological association between risk of PD and occupational exposure to rotenone, a naturally occurring pesticide that is a potent inhibitor of complex I of the mitochondrial respiratory chain (21); and an unusual form of acute parkinsonism was caused in a small number of patients by MPTP (1-methyl-4-phenylpyridinium) (22).

It is currently unclear how abnormalities of mitochondrial function and α-synuclein interact in the pathogenesis of PD. Overexpression of α-synuclein in cultured cells may alter mitochondrial function (23, 24), and oxidative stress resulting from mitochondrial impairment can influence α-synuclein expression and aggregation (25, 26). Snca−/− mice showed attenuated ROS production following inhibition of mitochondrial complex II with 3-nitropropionic acid (27). The dopaminergic neurons of some strains of Snca−/− mice were partially resistant to MPTP (28, 29). However, it is uncertain whether protection from MPTP is attributable to a pharmacokinetic mechanism unrelated to mitochondrial function. MPP+ (1-methyl-4-phenylpyridinium) is a substrate for the dopamine transporter (DAT), resulting in its selective uptake into dopaminergic terminals (30). Loss of α-synuclein has been reported to decrease cell surface expression of DAT in Snca−/− mice (31, 32) and cultured cells (33), which might attenuate MPTP toxicity by altering MPP+ uptake. However, studies showing that some strains of Snca−/− mice were protected against MPTP did not reveal any alteration in stri-
The Journal of Clinical Investigation

Research Article

Rats exposed chronically to rotenone show systemic reduction in the activity of complex I of the mitochondrial respiratory chain (34). The deficit is similar in magnitude to the systemic abnormalities in mitochondrial function reported in PD patients. Despite this systemic abnormality, rotenone-treated rats develop specific PD-like neuropathology, including progressive nigrostriatal degeneration and α-synuclein pathology (34). This model replicates many features of sporadic PD, including progressive parkinsonism responsive to dopaminergic medications; loss of dopaminergic neurons and their striatal terminals; depletion of endogenous antioxidants, oxidative damage to dopaminergic neurons, and iron deposition; microglial activation; and α-synuclein pathology in the enteric nervous system (34–37). In its original form, using intravenous administration via an osmotic minipump, the model was quite variable (34), and some researchers noted nonspecific systemic toxicity from rotenone (reviewed in ref. 36); and (ii) rotenone is highly lipophilic, and consequently its entry into cells is not dependent on expression of DAT that might be altered by decreasing α-synuclein levels.

In view of compelling evidence linking both α-synuclein and mitochondrial dysfunction to PD, we hypothesized that a critical pathogenic interaction between these factors occurs in vulnerable cell groups. We tested this hypothesis by asking whether reducing endogenous α-synuclein expression in the substantia nigra of adult rats prevented neurodegeneration in the rotenone model of PD. Our findings indicate that α-synuclein contributes to the selective vulnerability of nigral neurons to systemic mitochondrial complex I inhibition. This demonstrates a key mechanism for selective cell loss in PD and suggests that α-synuclein may be a valid target for further therapeutic development.

Results

Design and construction of a gene transfer vector targeting rat α-synuclein. We designed siRNAs to target regions of the rat Snca mRNA (encoding α-synuclein) that showed minimal homology to Snch or Sncb (encoding β- and γ-synucleins, respectively). Sequences showing significant homology to other genes by BLAST search (http://blast.ncbi.nlm.nih.gov/Blast.cgi) were rejected. We tested three siRNAs that satisfied these design criteria in a subclone of Chinese hamster ovary (CHO) cells stably transfected to express rat α-synuclein (Supplemental Figures 1 and 2; supplemental material online with this article; doi:10:1172/JCI64502DS1). Expression of α-synuclein was robustly reduced in vitro by two of these sequences (siRNA270, 75% knockdown; siRNA526, 85% knockdown). siRNA526 was chosen for further studies because there are multiple mismatches between the Snca, Snch, and Sncb genes at this location (Figure 1A). An shRNA corresponding to the sequence of siRNA526, expressed under transcriptional control of the U6 (RNA polymerase III) promoter, gave rise to progressive deposition; microglial activation; and oxidative damage to dopaminergic neurons, and iron deposition; microglial activation; and α-synuclein pathology in the enteric nervous system (34–37). In its original form, using intravenous administration via an osmotic minipump, the model was quite variable (34), and some researchers noted nonspecific systemic toxicity from rotenone (reviewed in ref. 36). However, recent refinements to this model — particularly the development of a reliable intraperitoneal delivery protocol using a triglyceride vehicle — have yielded more reproducible results, and rotenone has now been used in several species to model both motor and non-motor features of PD (reviewed in ref. 39). The rat rotenone model provides an appropriate setting in which to examine the role of endogenous α-synuclein in the pathogenesis of sporadic PD, because (i) the nigrostriatal dopaminergic lesion caused by rotenone is associated with α-synuclein–immunoreactive inclusion body pathology reminiscent of Lewy bodies (36); and (ii) rotenone is highly lipophilic, and consequently its entry into cells is not dependent on expression of DAT that might be altered by decreasing α-synuclein levels.

In view of compelling evidence linking both α-synuclein and mitochondrial dysfunction to PD, we hypothesized that a critical pathogenic interaction between these factors occurs in vulnerable cell groups. We tested this hypothesis by asking whether reducing endogenous α-synuclein expression in the substantia nigra of adult rats prevented neurodegeneration in the rotenone model of PD. Our findings indicate that α-synuclein contributes to the selective vulnerability of nigral neurons to systemic mitochondrial complex I inhibition. This demonstrates a key mechanism for selective cell loss in PD and suggests that α-synuclein may be a valid target for further therapeutic development.

Results

Design and construction of a gene transfer vector targeting rat α-synuclein. We designed siRNAs to target regions of the rat Snca mRNA (encoding α-synuclein) that showed minimal homology to Snch or Sncb (encoding β- and γ-synucleins, respectively). Sequences showing significant homology to other genes by BLAST search (http://blast.ncbi.nlm.nih.gov/Blast.cgi) were rejected. We tested three siRNAs that satisfied these design criteria in a subclone of Chinese hamster ovary (CHO) cells stably transfected to express rat α-synuclein (Supplemental Figures 1 and 2; supplemental material online with this article; doi:10:1172/JCI64502DS1). Expression of α-synuclein was robustly reduced in vitro by two of these sequences (siRNA270, 75% knockdown; siRNA526, 85% knockdown). siRNA526 was chosen for further studies because there are multiple mismatches between the Snca, Snch, and Sncb genes at this location (Figure 1A). An shRNA corresponding to the sequence of siRNA526, expressed under transcriptional control of the U6 (RNA polymerase III) promoter, gave rise to progressive loss of α-synuclein expression in vitro (Supplemental Figure 3).

We compared a number of different vectors for transduction of the substantia nigra in vivo (40) (Supplemental Figure 4). Adeno-associated virus serotype 2 (AAV2) vectors, recently shown...
to be safe in PD gene therapy clinical trials (41, 42), showed robust transgene expression in rat dopaminergic neurons and their striatal terminals (Figure 1B). An AAV2 vector (AAV-sh[SNCA]; Figure 1C) was constructed to express both shRNA526 and GFP, facilitating identification of transduced neurons in subsequent experiments. The control vector, AAV-sh[control], encoded a nontargeting shRNA but was otherwise isogenic to AAV-sh[SNCA].

For initial in vivo evaluation of the vectors, AAV-sh[SNCA] was infused into the substantia nigra unilaterally and AAV-sh[control] was infused on the contralateral side (rat cohort 1; see Table 1 for summary of experimental cohorts, interventions, and assays). Three weeks after vector transduction, gene expression was evaluated by RNA in situ hybridization (Figure 2A). Snca mRNA was not detected in dopaminergic neurons of the substantia nigra on the side that received AAV-sh[SNCA], whereas AAV-sh[control] did not affect Snca expression (Figure 2A). Expression of Sncb and Sncg was unaffected by either vector (Figure 2A), showing that AAV-sh[SNCA] targeted Snca specifically.

The enrichment of α-synuclein at presynaptic terminals poses a technical challenge for quantification of the protein in substantia nigra dopaminergic neurons: the majority of α-synuclein immunoreactivity in the substantia nigra is localized to terminals of axonal projections from other brain regions. Furthermore, α-synuclein in the striatal terminals of nigral dopaminergic neurons lies in close proximity to other populations of terminals and neurons. However, it was possible to measure the somatic component of α-synuclein immunoreactivity within tyrosine hydroxylase–expressing (TH-expressing) nigral neurons by confocal microscopy (Figure 3, A and B; Supplemental Figure 5). We quantified α-synuclein immunoreactivity in rats that received either AAV-sh[SNCA] or AAV-sh[control] unilaterally (cohort 2). Relative to nontransduced cells on the control side of the brain, α-synuclein expression in AAV-sh[SNCA]–transduced nigral dopaminergic neurons was reduced by ≈35% six weeks after surgery, whereas no change in α-synuclein expression was noted in neurons transduced with AAV-sh[control] (Figure 3, C and D). A similar reduction in α-synuclein expression was found in AAV-sh[SNCA]–transduced dopaminergic neurons in direct comparison with AAV-sh[control]–transduced neurons in animals that received bilateral vector transduction (cohort 1; Supplemental Figure 6).

Together these data show that AAV-sh[SNCA] caused a robust and specific reduction in Snca mRNA in substantia nigra dopaminergic neurons by 3 weeks after transduction and ≈35% loss of α-synuclein protein by 6 weeks after transduction. Specific α-synuclein knockdown in vivo does not cause loss of nigral dopaminergic neurons or their striatal terminals. A unilateral transduction design, in which separate animals received either AAV-sh[SNCA] or AAV-sh[control], was employed to reveal the impact of each vector independently on animal health (cohort 2). This allowed us to evaluate for possible toxic effects resulting from α-synuclein

---

### Table 1. Animal cohorts, interventions and assays discussed in the text

<table>
<thead>
<tr>
<th>Cohort</th>
<th>Experimental groups (no. rats)</th>
<th>Number of rats</th>
<th>Rotenone exposure</th>
<th>Analyses</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Ipsilateral AAV-sh[SNCA] + contralateral sh[control]</td>
<td>3</td>
<td>No</td>
<td>α-Synuclein quantification in nigral dopaminergic neurons</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Snca RNA in situ hybridization in nigra</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TH quantification in striatum</td>
</tr>
<tr>
<td>2</td>
<td>Unilateral AAV-sh[SNCA]</td>
<td>5</td>
<td>No</td>
<td>Postural instability test</td>
</tr>
<tr>
<td></td>
<td>Unilateral AAV-sh[control]</td>
<td>5</td>
<td></td>
<td>Cylinder/rearing test</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>α-Synuclein quantification in nigral dopaminergic neurons</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TH quantification in nigral dopaminergic neurons</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Snca RNA in situ hybridization in nigra</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TH quantification in striatum</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Stereological quantification of nigral dopaminergic neurons</td>
</tr>
<tr>
<td>3</td>
<td>Unilateral AAV-sh[SNCA]</td>
<td>4</td>
<td>No</td>
<td>Striatal neurochemistry</td>
</tr>
<tr>
<td></td>
<td>Unilateral AAV-sh[control]</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>No vector;</td>
<td>6</td>
<td>2.8 mg/kg daily to motor end point</td>
<td>Postural instability test</td>
</tr>
<tr>
<td></td>
<td>Unilateral AAV-sh[SNCA]</td>
<td>6</td>
<td></td>
<td>Cylinder/rearing test</td>
</tr>
<tr>
<td></td>
<td>Unilateral AAV-sh[control]</td>
<td>6</td>
<td></td>
<td>TH quantification in striatum</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Stereological quantification of nigral dopaminergic neurons</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dopaminergic neuron neurite quantification</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>α-Synuclein quantification in nigral dopaminergic neurons</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Snca RNA in situ hybridization in nigra</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TH quantification in nigral dopaminergic neurons</td>
</tr>
<tr>
<td>5</td>
<td>Ipsilateral AAV-sh[SNCA] + contralateral sh[control]</td>
<td>5</td>
<td>2.8 mg/kg daily to motor end point</td>
<td>TH quantification in striatum</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Stereological quantification of nigral dopaminergic neurons</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dopaminergic neuron neurite quantification</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Snca RNA in situ hybridization in nigra</td>
</tr>
<tr>
<td>6</td>
<td>No vector;</td>
<td>8</td>
<td>2.8 mg/kg daily for 6 days</td>
<td>Postural instability test</td>
</tr>
<tr>
<td></td>
<td>Unilateral AAV-sh[SNCA]</td>
<td>8</td>
<td></td>
<td>Cylinder/rearing test</td>
</tr>
<tr>
<td></td>
<td>Unilateral AAV-sh[control]</td>
<td>8</td>
<td></td>
<td>TH quantification in striatum</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Snca RNA in situ hybridization in nigra</td>
</tr>
</tbody>
</table>
knockdown. Immediate postoperative weight loss was identical in the two groups, and there were no significant differences in weight gain during the subsequent recovery period (Figure 4A). We evaluated both sets of animals for asymmetry in motor function that would indicate physiologically significant disturbances of nigral function provoked by vector transduction. We employed two complementary tests that are sensitive to dopaminergic function and useful for detecting unilateral deficits (36, 43, 44). The postural instability test evaluates evoked forepaw movements in a postural control paradigm, whereas the cylinder test evaluates spontaneous forepaw movements during exploration of a behavioral arena (43, 44). Neither AAV-sh[SNCA]– nor AAV-sh[control]–transduced animals showed any significant differences between left and right forepaw function in these tests at any time point up to 6 weeks after surgery (Figure 4, B–D).

We next analyzed the nigrostriatal system histologically. Unbiased stereology did not show loss of dopaminergic neurons in the AAV-sh[SNCA]–transduced substantia nigra relative to the control side that was not exposed to vector (Figure 5A). Confocal microscopy showed no significant difference in TH expression between nigral neurons on the nontransduced control side of the brain and neurons transduced with either AAV-sh[SNCA] or AAV-sh[control] (Figure 5, B and C). Quantitative near-infrared immunofluorescence (Supplemental Figure 7) showed no significant difference in striatal TH expression ipsilateral to nigral AAV-sh[SNCA] or AAV-sh[control] transduction compared with the nontransduced control side (Figure 5, D, E, and F).

Finally, we analyzed neurochemical end points following α-synuclein knockdown, in view of emerging evidence that α-synuclein may be involved in regulating dopamine storage and release at striatal terminals (31, 45). The substantia nigra was transduced unilaterally with either AAV-sh[SNCA] or AAV-sh[control] (cohort 3); dopamine and its metabolites were measured in freshly dissected striatal tissue at 42 days after transduction. The striatum ipsilateral to nigral AAV-sh[SNCA] transduction showed ≈20% reduction in dopamine content compared with the nontransduced side, whereas no difference was apparent between the two sides in AAV-sh[control] animals (Figure 5F). Dopamine turnover, estimated by the ratio of the dopamine metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) to dopamine, was unchanged following α-synuclein knockdown (Figure 5G).

Together, these data provide no evidence that either vector transduction or knockdown of endogenous α-synuclein caused degeneration of substantia nigra dopaminergic neurons or their striatal terminals. However, α-synuclein knockdown caused a modest reduction in striatal dopamine content that was not attributable to reduced TH expression, and which did not result in any detectable deficit in motor function.

Loss of α-synuclein prevents progressive motor deficits in the rotenone model of PD. We next evaluated the role of α-synuclein in the pathogenesis of the rotenone model of PD. Experiments were conducted using both unilateral and bilateral transduction designs. In unilateral transduction experiments, rats received either AAV-sh[SNCA] or AAV-sh[control] in the substantia nigra on one side (cohort 4). This enabled us to evaluate the effects of α-synuclein knockdown and control vector on survival to end point and motor function in separate animals, in comparison with a third group of animals that did not receive vector. In bilateral transduction experiments, rats received AAV-sh[SNCA] in the substantia nigra on one side and AAV-sh[control] in the other (cohort 5). This enabled direct comparison between the knockdown and control vectors in histological end points. Since the nigrostriatal dopaminergic lesion and associated motor deficits resulting from chronic systemic rotenone exposure are characteristically bilateral and symmetric (36), the two sides of each animal were compared, both in motor assays and by assessment
of histological end points, to reveal the contribution of α-synuclein to pathogenesis. Analysis of samples from cohort 4 by quantitative confocal microscopy verified that AAV-sh[SNCA]–induced α-synuclein knockdown persisted following rotenone exposure (Supplemental Figure 8).

There was no difference in weight loss among no-vector control, AAV-sh[control]–, and AAV-sh[SNCA]–transduced rats during rotenone exposure (Figure 6A). There was also no difference in the time that rats from each experimental group were determined to have reached the approved study end point of >20% weight loss or severe generalized hypokinesia (Figure 6B). However, rats that received AAV-sh[SNCA] unilaterally in the right substantia nigra showed significant rescue of motor abnormalities in the contralateral left forelimb (Figure 6, C and D), which was not observed in the AAV-sh[control] or no-vector groups.

In the postural instability test, the displacement necessary to trigger a corrective forelimb movement is augmented when nigral dopaminergic function is impaired on the contralateral side. In rats that received either no vector or AAV-sh[control], the distance to provoke a corrective movement increased progressively and symmetrically during rotenone exposure, from a mean baseline value of 3.1 cm to 5.2 cm by 8 days of rotenone exposure (this was the latest time point at which assays of motor function were carried out). In contrast, the left forelimbs of rats that received AAV-sh[SNCA] in the contralateral right substantia nigra showed only a small increase in the displacement necessary to provoke a corrective movement, from 3.1 cm at baseline to 3.6 cm by day 8 of rotenone exposure. The right forelimbs of the same animals showed an increase from 3.13 cm to 5.5 cm, similar to that observed in no-vector and AAV-sh[control] animals. The differences between AAV-sh[SNCA] animals and other experimental groups, and between the left and right forelimbs of AAV-sh[SNCA] animals, were statistically significant by day 4 of rotenone exposure. These differences became larger as rotenone-induced motor abnormalities progressed, and by day 6 were highly statistically significant (left forepaw of AAV-sh[SNCA] versus other groups, \( P = 0.00000016 \), 1-way ANOVA; right versus left forepaw of AAV-sh[SNCA] animals, \( P = 0.00000052 \), 2-tailed paired t test).

Figure 3. AAV-sh[SNCA] reduces α-synuclein expression in substantia nigra dopaminergic neurons. Two groups of 5 rats received either AAV-sh[SNCA] or AAV-sh[control] unilaterally in the substantia nigra (cohort 2). Forty-two days later, midbrain sections were immunolabeled for TH (green), α-synuclein (red), and DAPI (blue). Measurements of α-synuclein immunoreactivity were taken from nontransduced (white triangles), AAV-sh[control]–transduced (gray circles), or AAV-sh[SNCA]–transduced (black squares) substantia nigra dopaminergic neurons. (A and B) High-magnification confocal images of the substantia nigra from (A) no-vector and (B) AAV-sh[SNCA]–transduced sides of a single section. The positions of dopaminergic neuronal outlines revealed by TH labeling are shown as white dotted lines in the α-synuclein channel. Scale bars: 10 μm. (C) Cytoplasmic α-synuclein immunoreactivity was quantified in 60–100 nigral dopaminergic neurons on each side of each section by confocal imaging. The small markers show α-synuclein immunofluorescence signal for each cell on the vector-transduced side expressed as percentage of the mean value for dopaminergic neurons on the nontransduced side of the same section. The large markers show mean ± SEM for each animal. (D) Mean dopaminergic neuron α-synuclein immunofluorescence is shown for each side of the brain in each animal (+, vector side; −, nontransduced side; lines join the means for the two sides of each brain). The left graph shows measurements from animals that were transduced with AAV-sh[control] and the right AAV-sh[SNCA]. Large markers show mean ± SEM for all five animals in each group.*\( P < 0.05 \), **\( P < 0.01 \), ***\( P < 0.001 \), 2-tailed paired t test, vector transduced side versus control side.
Spontaneous cylinder exploration was severely reduced from the onset of rotenone treatment as a result of systemic rotenone toxicity. Consequently, counting unilateral forepaw wall contacts during rearing behavior performed relatively poorly as a quantitative assay for motor asymmetry in this model. However, after 8 days of rotenone treatment, the remaining AAV-sh[SNCA] rats all showed some spontaneous exploratory behavior and rearing movements, whereas only one of the remaining AAV-sh[control] controls and none of the no-vector controls produced any spontaneous movements (\( \chi^2 = 10.31, P < 0.05 \)). At this time point, AAV-sh[SNCA]–transduced rats showed significantly more rearing movements with unilateral left forelimb wall contacts than controls (\( P = 0.0063, 1\)-way ANOVA), whereas there was no significant difference in the number of rears with right forelimb wall contacts among the three groups.

Together, these data show that nigral \( \alpha \)-synuclein knockdown prevented progressive loss of evoked contralateral forelimb movement, and partially rescued contralateral spontaneous forelimb movements, during chronic rotenone exposure.

\( \alpha \)-Synuclein knockdown is neuroprotective in the rotenone model of PD. Neuropathological examination of samples from cohorts 4 and 5 showed that the preservation of neurological function contralateral to \( \alpha \)-synuclein knockdown seen in cohort 4 was associated with neuroprotection on the side of the brain that received AAV-sh[SNCA] (Figures 7–9).

Loss of dopaminergic presynaptic terminals in the dorso-lateral striatum was clearly visible in hemispheres that received AAV-sh[control] or no vector, similar to lesions previously reported in this model (36). In contrast, the striatum ipsilateral to AAV-sh[SNCA] transduction did not show overt loss of striatal dopaminergic terminals (Figure 7, A and B). As an objective measure of striatal dopaminergic terminal integrity, quantitative near-infrared immunofluorescence was employed to measure dorsolateral striatal TH immunoreactivity in multiple tissue sections encompassing the rostrocaudal extent of the striatum (Supplemental Figure 7). Significant preservation of striatal dopaminergic terminals was found on the AAV-sh[SNCA]–transduced side compared with either the no-vector side (cohort 4; \( P = 0.0097, 2\)-tailed paired \( t \) test; Figure 7F) or the AAV-sh[control] side (cohort 5; \( P = 0.0063, 2\)-tailed paired \( t \) test; Figure 7D). In contrast, there was no significant difference between the AAV-sh[control] side and the no-vector side (cohort 4; \( P = 0.629, 2\)-tailed paired \( t \) test; Figure 7E). Furthermore, relative to the control left side, striatal TH immunoreactivity on the right side was significantly greater in animals that received unilateral AAV-sh[SNCA] than separate control animals that received AAV-sh[control] or no vector (Supplemental Figure 9A; cohort 4; \( P = 0.016, 1\)-way ANOVA). \( \alpha \)-Synuclein knockdown thus protected striatal dopaminergic terminals from rotenone; overall, 25%–40% more TH signal was detected in the striatum ipsilateral to AAV-sh[SNCA] transduction than in control striatum at the experimental end point.

Severe rotenone-induced degeneration of substantia nigra dopaminergic neurons was observed in nontransduced and AAV-sh[control] samples. This neuronal loss was attenuated on the AAV-sh[SNCA] side in both cohorts 4 and 5 (Figure 8 and Supplemental Figure 9B). Unbiased stereological quantification confirmed that there were significantly more dopaminergic neurons remaining on the AAV-sh[SNCA] side compared with either the AAV-sh[control] side (cohort 5; \( P = 0.007, 2\)-tailed paired \( t \) test; Figure 8B) or no-vector...
Figure 5. Preserved nigrostriatal morphology and TH expression, but reduced striatal dopamine content, following α-synuclein knockdown. Animals from cohorts 2 (A-E) and 3 (F and G) were analyzed for changes in the nigrostriatal system following unilateral α-synuclein knockdown. Measurements from the nontransduced (white triangles), AAV-sh[control]–transduced (gray circles), and AAV-sh[SNCA]–transduced (black squares) sides of each brain are shown. In A, C, and E–G, small markers show data points from each individual animal (the two sides of each brain are connected by a line); large markers show the group mean ± SEM. (A) Unbiased stereology was employed to quantify the number of nigral dopaminergic neurons on each side of the brain. (B and C) TH expression was measured in nigral dopaminergic neurons by confocal microscopy. In B, measurements for individual neurons are shown normalized to nontransduced cells in the same sections (small markers). Large markers show mean ± SEM for each animal. (D and E) Striatal TH expression was measured using quantitative near-infrared immunofluorescence. In D, measurements in individual sections are shown normalized to the nontransduced side of the same section (small markers). Large markers show mean ± SEM for each animal. (F and G) HPLC was employed to quantify dopamine levels (F) and the ratio of dopamine metabolites to dopamine (G) as an index of dopamine turnover. Data were analyzed using 2-tailed paired t tests comparing the vector-transduced and control sides of each brain; *P < 0.05.

The dendritic processes of dopaminergic neurons remaining in the nontransduced and AAV-sh[control]–transduced substantia nigra following rotenone exposure showed evidence of severe damage. This was mitigated in AAV-sh[SNCA]–transduced substantia nigra. We measured the total length of neuritic processes per surviving dopaminergic neuron, using an automated algorithm, as an objective measure of dendritic integrity. Significant preservation of neurites was found in the AAV-sh[SNCA]–transduced side compared with either the no-vector side (cohort 4; P = 0.0013, 2-tailed paired t test; Figure 9D) or the AAV-sh[control] side (cohort 5; P = 0.0068, 2-tailed paired t test; Figure 9B). In contrast, there was no significant difference between the AAV-sh[control] side and the no-vector side (cohort 4; P = 0.74, 2-tailed paired t test; Figure 9C). Furthermore, relative to the control left side, the total length of processes per nigral dopaminergic neuron was greater in animals that received unilateral AAV-sh[SNCA] than separate control animals that received AAV-sh[control] (Supplemental Figure 9C; cohort 4; P = 0.0078, 2-tailed unpaired t test). α-Synuclein knockdown thus protected the dendrites of nigral dopaminergic terminals from rotenone; dopaminergic neurons in the AAV-sh[SNCA]–transduced substantia nigra showed overall 60% more total neurite length than controls. Similar differences between experimental groups were also found in neurite segments and branches (Supplemental Figure 11).

Together, these data show that α-synuclein knockdown protected substantia nigra dopaminergic neurons, their dendrites, and their striatal terminals from degeneration in the rotenone model of PD.
control and AAV-sh[SNCA] sides (Figure 10, B and C), suggesting that the motor deficits found at this time point reflect loss of function rather than degeneration of striatal dopaminergic terminals. Consequently, we conclude that α-synuclein knockdown protects dopaminergic terminals from rotenone-induced functional impairment as an early event that precedes morphological abnormalities such as degeneration of nigral neurons and their terminals.

Discussion

We have demonstrated that knockdown of endogenous α-synuclein in the adult brain ameliorates pathology in an animal model of sporadic PD. Knockdown of the protein by ≈35% in the cell bodies of nigral dopaminergic neurons mitigated nigral α-synuclein accumulation, and protected motor function, striatal dopaminergic terminals, nigral dopaminergic neurons and their dendrites in the rotenone model of PD. These findings represent a significant advance in determining how genetic and environmental factors interact in PD pathogenesis, add to the current understanding of the physiological role of α-synuclein in the adult brain, and are important because...
α-synuclein knockdown has a neuroprotective effect in the rotenone model of Parkinson’s disease. The integrity of striatal dopaminergic terminals was analyzed after rotenone exposure in cohort 4 (unilateral vector transduction, E and F) and cohort 5 (bilateral vector transduction, A-D). (A) Near-infrared immunofluorescence scan, showing TH expression (green) in a coronal section of the forebrain; the plane of the section is indicated in the inset. The white arrow shows loss of TH signal in the dorsolateral striatum on the AAV-sh[control] side; no lesion was seen on the AAV-sh[SNCA] side. Scale bar: 1 mm. (B) Forebrain sections were immunolabeled for TH expression (brown). The micrographs show the dorsolateral striatum on each side of brains from cohort 1 (upper panels; bilateral vector transduction, no rotenone) and cohort 5 (lower panels; bilateral vector transduction, post-rotenone). Scale bar (for all four panels): 100 μm. (C-F) Dorsolateral striatal TH signal was measured by quantitative near-infrared immunofluorescence. (C) Cohort 5: striatal TH signal on the AAV-sh[SNCA] side of each section is shown as a percentage of the signal measured on the AAV-sh[control] side of the same section. Small markers show individual sections; large markers show mean ± SEM for each animal. (D, E, and F) Mean striatal TH signal is shown for cohorts 5 (D) and 4 (E and F). The two sides from each animal are shown as small markers connected by lines; large markers show group mean ± SEM. **P < 0.01, ***P < 0.001, AAV-sh[SNCA] side versus contralateral side, 2-tailed paired t test.
also has face validity. By exploiting the rotenone model, we have demonstrated for the first time to our knowledge that knockdown of endogenous α-synuclein in the adult brain ameliorates PD-like neurodegeneration in vivo. This is an important finding with implications for translational research, because these data suggest that selective targeting of α-synuclein by shRNA may be a valid therapeutic approach for neuroprotection in sporadic PD.

Further consideration of shRNA gene delivery as a therapeutic approach will be influenced in part by the prospect of toxicity arising from loss of α-synuclein in the adult brain. Germline deletion of the Snca gene did not give rise to significant adverse effects; multiple independent murine Snca–/– lines were viable and did not show overt nigral pathology (28, 29, 45, 58), although a recent study suggested that a developmental mechanism occurring between E10.5 and E13.5 caused the number of nigral dopaminergic neurons in Snca–/– mice to be approximately 30% less than controls in one strain of Snca–/– mice (59). Interestingly, some animal species, including zebrafish (60) and a naturally occurring murine strain (61), spontaneously lost the Snca gene without compromised survival or motor function. This suggests that α-synuclein may be dispensable, possibly due to compensa-

Figure 8. α-Synuclein knockdown protects substantia nigra dopaminergic neurons in the rotenone model of Parkinson’s disease. The number of substantia nigra dopaminergic neurons remaining after chronic rotenone exposure was determined in cohorts 4 (unilateral vector transduction) and 5 (bilateral vector transduction). (A) Confocal micrographs show the substantia nigra from a representative midbrain section derived from a rat that received AAV-sh[control] on one side (left panel) and AAV-sh[SNCA] on the other (right panel) prior to chronic rotenone exposure. There was striking loss of dopaminergic neurons on the AAV-sh[control] side, as expected following chronic rotenone exposure using this regimen. In contrast, the AAV-sh[SNCA] side showed evidence of neuroprotection. Scale bar: 200 μm. (B–D) Unbiased stereology was used to determine the total number of remaining substantia nigra dopaminergic neurons on each side of the brain in cohorts 4 (unilateral vector transduction; C and D) and 5 (bilateral vector transduction; B). The stereological count for each individual animal is shown (small markers; data for the two sides of each brain are connected by a line). Large markers show the group mean ± SEM. White triangles, nontransduced side; gray circles, AAV-sh[control]–transduced side; black squares, AAV-sh[SNCA]–transduced side. **P < 0.01, 2-tailed paired t test, AAV-sh[SNCA] side versus contralateral side.

The discovery of pathogenic SNCA gene mutations in rare parkinsonism phenocopies (10, 12) and the prominence of α-synuclein pathology in sporadic PD (2, 48) led to consideration of shRNA targeting α-synuclein expression as a possible neuroprotective intervention in PD (49). However, this has been difficult to test in the absence of suitable models. Transgenic mice overexpressing α-synuclein have not been reported to develop robust degeneration of substantia nigra dopaminergic neurons, precluding their use to evaluate neuroprotective agents (including gene transfer vectors targeting SNCA) (50–55). The commonly employed MPTP and 6-OHDA toxin models of PD are associated with acute lesions that do not typically show synucleinopathy (56). Chronic exposure to MPTP did result in synucleinopathy (57), but attempts at therapeutic α-synuclein knockdown during adulthood have not been reported in this model. Furthermore, neither MPTP nor 6-OHDA has been etiologically associated with typical PD in humans. Occupational rotenone exposure is implicated as an environmental risk factor in typical sporadic PD (21), suggesting that the rotenone model of PD may have etiological (construct) validity. In addition, this model replicates numerous key features of PD, including progressive nigral dopaminergic neuron degeneration and α-synuclein pathology, suggesting that the model
transduction resulting in ≈35% knockdown of α-striatal TH-expressing terminals, or loss of dopaminergic neurons, we observed no abnormalities in motor function, loss of striatal integrity were not reported. Consistent with these previous reports, we observed no abnormalities in motor function, neurochemistry, and histological end points for nigrosome after the procedure. No overt toxicity was noted, although motor dysfunction in the midbrain (45%), striatum (43%), and cortex (24%) by 7 days posttransduction in the previous study (64), found at 4 weeks after transduction in the previous study (64), whereas we used AAV2. This may have changed the efficiency with which transgene DNA was delivered to neurons. (iii) The previous study used an H1 promoter to drive shRNA expression, whereas we employed a U6 promoter. This may have altered the relative expression levels of the shRNA in dopaminergic neurons. In combination, these methodological differences may account for the reported disparity in the level of α-synuclein knockdown: 70%–85% loss of nigral α-synuclein expression was found at 4 weeks after transduction in the previous study (64), compared with ≈35% knockdown at 6 weeks in the present work. Consequently, it is possible that the degree of acute α-synuclein knockdown determines whether toxicity occurs. An alternative interpretation is that the neurodegeneration reported previously may have been attributable to factors other than loss of α-synuclein. This is compatible with other work showing that an AAV-H1:shRNA vector targeting human, but not rat, SNCA was toxic in the rat substantia nigra (as was a similar vector expressing shRNA targeting luciferase), suggesting that nonspecific toxicity from shRNA expression at high levels may be important (67, 68). Regardless, the absence of neurodegeneration resulting from α-synuclein knockdown in our study is compatible with findings in a range of other model systems (28, 29, 45, 58, 61, 63). These data show that α-synuclein can be targeted in vivo in the adult brain without causing cell death.

Even though we did not observe dopaminergic cell loss in our study, the striatum ipsilateral to AAV-sh[SNCA] transduction of β- and γ-synucleins (62). However, acute knockdown of Snca in the adult brain could potentially cause unwanted effects by circumventing developmental compensatory mechanisms that occur in germline null mutants. There are four previous reports of RNAi-mediated knockdown of endogenous α-synuclein in the adult CNS in vivo (63–66). Naked siRNA infused into the mouse hippocampus gave rise to a significant 60%–80% reduction in Snca mRNA and a qualitative decrease in α-synuclein protein levels, but no overt cell loss or microgliosis (65). Naked siRNA infused into the primate midbrain caused a 50% reduction in SNCA mRNA, associated with a 40% reduction in α-synuclein. There was no inflammation, loss of nigral dopaminergic neurons, changes in the concentrations of striatal dopamine or its metabolites, or other toxicity (63). More recently, exosomes bearing a Lamp2b-RVG (rabies virus glycoprotein) fusion protein to target delivery to neurons were administered systemically in mice (66). Expression levels of α-synuclein were reduced in the midbrain (45%), striatum (43%), and cortex (24%) by 7 days after the procedure. No overt toxicity was noted, although motor function, neurochemistry, and histological end points for nigrostrial integrity were not reported. Consistent with these previous reports, we observed no abnormalities in motor function, loss of striatal TH-expressing terminals, or loss of dopaminergic neurons or damage to their dendrites 6 weeks after AAV-sh[SNCA] transduction resulting in ≈35% knockdown of α-synuclein.

In contrast, a single previous study unexpectedly found rapidly progressive neurodegeneration in rats following AAV-mediated delivery of shRNA directed at the Snca transcript (64). TH-immunoreactive neurons were depleted in the nigra by more than 90% at 4 weeks after transduction, and this was associated with loss of striatal TH expression and asymmetric evoked motor function. It is unclear why these outcomes differ so dramatically from our work, and from other work employing naked siRNA or exosome delivery to target the SNCA transcript. Although both AAV-shRNA studies (ref. 64 and the present work) used the same vector dose (4 × 10⁹ vector genomes/side), there were multiple methodological differences: (i) The shRNA sequences differed between the studies. This may have influenced the level of knockdown or the possibility of off-target effects. (ii) The previous study used an AAV2/5 pseudotype to deliver shRNA, whereas we used AAV2. This may have changed the efficiency with which transgene DNA was delivered to neurons. (iii) The previous study used an H1 promoter to drive shRNA expression, whereas we employed a U6 promoter. This may have altered the relative expression levels of the shRNA in dopaminergic neurons. In combination, these methodological differences may account for the reported disparity in the level of α-synuclein knockdown: 70%–85% loss of nigral α-synuclein expression was found at 4 weeks after transduction in the previous study (64), compared with ≈35% knockdown at 6 weeks in the present work. Consequently, it is possible that the degree of acute α-synuclein knockdown determines whether toxicity occurs. An alternative interpretation is that the neurodegeneration reported previously may have been attributable to factors other than loss of α-synuclein. This is compatible with other work showing that an AAV-H1:shRNA vector targeting human, but not rat, SNCA was toxic in the rat substantia nigra (as was a similar vector expressing shRNA targeting luciferase), suggesting that nonspecific toxicity from shRNA expression at high levels may be important (67, 68). Regardless, the absence of neurodegeneration resulting from α-synuclein knockdown in our study is compatible with findings in a range of other model systems (28, 29, 45, 58, 61, 63). These data show that α-synuclein can be targeted in vivo in the adult brain without causing cell death.
The mechanisms underlying these changes are unclear but are thought to reflect a reduction in dopamine synthesis, reuptake, or storage occurring in the absence of α-synuclein, as part of a wider picture of alterations in neurotransmitter handling at dopaminergic terminals. These data raise the intriguing possibility that functions of α-synuclein involved in dopamine handling and storage are relevant to the protection of dopaminergic terminal function that we observed as an early event in the rotenone model following α-synuclein knockdown. Dopamine oxidation products exert a highly deleterious effect on mitochondrial function (69), and it is conceivable that reduced dopamine stores in striatal terminals are one component of the neuroprotective effect of α-synuclein knockdown in the rotenone model.

In summary, this is the first demonstration to our knowledge that knockdown of endogenous α-synuclein in the adult substantia nigra attenuates motor deficits and neurodegeneration in an animal model of PD. Given the demonstrated safety of AAV2 vectors in human PD gene therapy trials, this approach has significant translational potential and should be evaluated further as a possible neuroprotective intervention.

**Methods**

**Viral vectors.** AAV-sh[SNCA] and AAV-sh[control] were generated by ligating annealed oligonucleotides encoding sh526 (Figure 1A) or a control sequence (5′-AATTCTCCGAACGTGTCACGT-3′) into the BamHI/EcoRI sites of pAAV-D(+)-U6-siRNA-CMV-GFP, which was derived from pAAV-D(+)-U6-siRNA-CMV-zsGreen (a gift from Bing Wang, University of Pittsburgh) by replacing the zsGreen open reading frame with GFP. Vectors were prepared to high titer and purity by plasmid co-transfection in 293 cells at the University of Pennsylvania Vector Core. Animals were anesthetized with isoflurane (induction 3%, maintenance 2%-3%). Viral vector delivery parameters were optimized for infusion site, delivery volume, rate of delivery, infusion needle type, vector type (lentivirus [ref. 40], herpes simplex virus, AAV [AAV2, -2/1, -2/9]) (Supplemental Figure 4), vector concentration, and number of infusions in a series of pilot experiments. In the experiments shown, 2 µl viral vector suspension was infused dorsal to the substantia nigra (~5.8 mm anterior/posterior, ±2.2 mm right/left, ~7.5 mm ventral to bregma) using a Hamilton syringe with a 30-gauge needle (45° bevel) at a rate of 0.2 µl/min. AAV-sh[SNCA] and AAV-[control] were used at the same concentration, 2.0 × 1012 GC/ml, total dose 4.0 × 1012 GC/side.

**Animals.** Adult male Lewis rats of approximately 6 months of age were obtained from Hilltop Lab Animals and Charles River.

**Rotenone.** Animals in cohorts 1, 2, and 3 were evaluated without rotenone treatment 21 or 42 days after viral vector infusion. Animals in cohorts 4, 5, and 6 received daily intraperitoneal rotenone (2.8 mg/kg/d) (36) starting 21 days after vector infusion. Animals were monitored daily for weight loss and motor signs, and rotenone was continued until the experimental end point defined by weight loss of >20% or severe bilateral bradykinesia. Motor tests were carried out every 2 days during rotenone exposure and were performed exactly as published in our previous work (36).

**Neurochemistry.** Striatal tissue samples were sonicated on ice in 0.1 M perchloric acid and centrifuged for 30 minutes at 16,100 g. The supernatant was collected and filtered in Costar Spin-X 0.22-µM nylon
membrane polypropylene centrifuge tubes at 1,000 g, then injected into a Waters 2695 HPLC separation module at 4°C. The HPLC mobile phase consisted of 0.05 M sodium phosphate, 0.01 M citric acid, 0.01 M sodium acetate, 10% methanol, 0.32 mM octyl sulfate sodium salt, 0.1 mM ethylenediaminetetraacetic acid, pH 2.5. The flow rate was 0.8 ml/min. Neurotransmitters were separated on a Varian Microsorb-b-MVC18 4.6 × 250-mm column with a 5-μm particle size and detected on a Waters 2465 electrochemical detector with a glassy carbon electrode set at 750 mV referenced to an ISAAC electrode at 28°C. Quantification was carried out by comparison with high purity standards.

Histology. Animals were deeply anesthetized with pentobarbital (50 mg/kg) and perfused-fixed with PBS and 4% paraformaldehyde. Brains were post-fixed, cryoprotected, and sectioned (35 μm) using a sliding freezing-stage microtome. Dopaminergic terminal density in the striatum was determined by measuring TH immunofluorescence as previously described (40) (Supplemental Figure 6). Antibodies were primary mouse anti-TH (1:2,000; 48 hours at 4°C; Millipore, MAB318); and secondary donkey anti-mouse (1:500; 2 hours at 20°C; LI-COR, IRDye 800CW). Sections were imaged using a LI-COR infrared scanner. Regions of interest were drawn in the striatum as shown in Supplemental Figure 6, and mean fluorescence intensity was calculated. To quantify α-synuclein expression in nigral neurons, midbrain sections were colabeled for GFP to identify transduced neurons (1:4,000; Millipore, MAB3580; secondary Alexa Fluor 488-anti-mouse, 1:500); tyrosine hydroxylase to identify dopaminergic neurons (1:2,000; Millipore, AB152; secondary Cy3–anti-rabbit, 1:500); and α-synuclein (1:3,000; Millipore, AB5334P; secondary Cy5–anti-sheep, 1:500). Images were acquired using an Olympus FV-1000 confocal microscope, with constant laser and detector settings that were optimized to avoid saturation in the α-synuclein and TH channels. Regions of interest were drawn around at least 60 transduced (GFP+) dopaminergic (TH+) neurons on each side of each animal, allowing calculation of mean α-synuclein and TH immunofluorescence.

Unbiased stereology. One in every six coronal midbrain sections was immunolabeled for MAP2 (1:2,000, Millipore; secondary Alexa Fluor 647-anti-mouse, 1:500); Invitrogen) and TH (1:3,000, Millipore, secondary Cy3–anti-sheep, 1:500; Jackson ImmunoResearch Laboratories Inc.). Images were acquired using an automated Nikon 90i upright widefield microscope with a 20× objective (NA 0.75), equipped with a linear-encoded motorized stage and Qimaging Retiga cooled CCD camera. Micrographs were analyzed using NIS-Elements software. A region of interest was drawn around the substantia nigra, and neurons were quantified by a single investigator blinded to whether the animals had received rotenone or viral vector. The software counted all cells in which MAP2, TH, and H33342-positive nuclei coincided. The method yields identical results to manual stereology, but has a lower coefficient of error (<0.05 for each animal) owing to the much greater number of neurons sampled (70, 71). Neurite architecture was analyzed using the automated Surpass FilamentTracer module of Imaris software (version 7.1.1, Bitplane), employing a skeletonized algorithm.

RNA in situ hybridization. AAV-shSNCA–induced nigral Snca knockdown was verified by RNA in situ hybridization in midbrain sections from all animals of cohorts 1, 2, 4, 5, and 6. Probe templates were amplified from rat brain RNA by RT-PCR using primers to Snca (F: 5′-AGATGAGTGTTGCTCAGAAG-3′, R: 5′-TCTG-TAGGCTTACAGTCTCATA-3′); Sncb (F: 5′-CCGCCAGGATGAGCTG-TGTTCAT-3′, R: 5′-ATGGACCCCTTTACGCCCTC3′); and Sncg (F: 5′-AGCAGCCAGTCTTCTC-3′, R: 5′-TGGAAGCCCTTCTAGT-CACTC-3′). Products were cloned and sequence verified. Digoxigenin-labeled cRNA probes were generated by in vitro transcription of linearized plasmid. Fixed, free-floating brain sections were washed in PBS, then treated with 0.1% diethylpyrocarbonate (DEPC) in PBS for 15 minutes, equilibrated in 5× SSC, postfixed in 4% PFA, and washed in PBS. Sections were then incubated in ULTRAhyb (Ambion) supplemented with 1 mg/ml Torula RNA (Sigma-Aldrich) for 1 hour at 68°C. Labeled cRNA probe was then added to a final concentration of 150 ng/ml and hybridized at 68°C overnight. Hybridization buffer and unbound probe were removed by washing in 2× SSC; stringency washes were carried out at 68°C in 0.1× SSC. Hybridized probe was localized using alkaline phosphatase–conjugated (AP-conjugated) anti-digoxigenin antibody (Roche) and bound antibody detected by a histochemical reaction using an AP substrate (BM Purple, Roche).

Statistics. Experiments were powered to detect >10% differences in histological and neurochemical end points between treatment conditions and >20% differences in behavioral end points, with α = 0.05 and β = 0.8, using expected effect sizes and variances estimated from our pilot studies. Two-tailed paired t test was employed to compare morphological end points, protein expression data, and neurochemical measurements from the two sides of the same brains. One-way ANOVA with Tukey’s post hoc test was used to compare motor function and weight of different animals from multiple treatment groups. One-way ANOVA (three experimental groups) or two-tailed unequal t test assuming unequal variance (two experimental groups) was used to compare histological end points from separate animals in different experimental groups. Categorical data were analyzed using a χ2 test. Survival data were analyzed using a log-rank test.

Study approval. Experiments were approved by the Institutional Animal Care and Use Committees of both the Pittsburgh Veterans’ Affairs Healthcare System and the University of Pittsburgh.

Acknowledgments

This work was supported by research grants from the United States Department of Veterans’ Affairs (I01BX000548), the NIH (ES022644, NS059806, ES018058, ES020718, ES019879, ES020327), the Blechman Foundation, the Parkinson’s Chapter of Greater Pittsburgh, the JPB Foundation, the American Parkinson Disease Association, and the Parkinson’s Unity Walk, and a generous gift from Mr. and Mrs. Henry Fisher. The contents of this article do not represent the views of the US Department of Veterans Affairs or the United States Government. The authors thank Thomas Sew and Amanda Mortimer for technical assistance.

Address correspondence to: Edward A. Burton, University of Pittsburgh, 7015 BST-3, 3501 Fifth Avenue, Pittsburgh, Pennsylvania 15213, USA. Phone: 412.648.8480; E-mail: eab25@pitt.edu.

Jason R. Cannon’s present address is: School of Health Sciences, Purdue University, West Lafayette, Indiana, USA.

Amina El Ayadi’s present address is: Department of Surgery, University of Texas Medical Branch, Galveston, Texas, USA.

Alevtina D. Zharkov, Jason R. Cannon, and Victor Tapia contributed equally to this work and are co-first authors.
40. Bonifati V, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset par-
The Journal of Clinical Investigation


